235 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1755)
- Addiction (19)
- Allergy, Asthma, & Immunology (13)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (29)
- Blood Disorders (33)
- Bone & Muscle (10)
- Cancer
(564)
- (-) Bladder Cancer (13)
- Brain Cancer (12)
- Breast Cancer (60)
- Gastrointestinal (10)
- Gynecologic Cancer (30)
- Head and Neck Cancer (4)
- Kidney Cancer (7)
- Leukemia (64)
- Liver Cancer (4)
- Lung Cancer (57)
- Lymphoma (24)
- Multiple Myeloma (24)
- Pancreatic Cancer (6)
- Prostate Cancer (25)
- Sarcoma (23)
- Skin Cancer (26)
- Solid Tumors (36)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (49)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (53)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (165)
- Nutrition (6)
- Obesity (10)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (103)
- Psychiatric Disorders (69)
- Rehabilitation (9)
- (-) Stroke (7)
- Surgery (7)
- Transplant (48)
- Urology (4)
- Vascular Conditions (10)
Displaying 1 - 31 of 31
Condition: Stroke
Investigator: Sunil Agrawal, PhD
Status: Currently Recruiting
A Tethered Pelvic Assist Device (TPAD) will provide wearers with gentle forces to evaluate the effects on walking.
Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to determine whether using LY4052031 in a type of cancer that may have tumor cells that express a protein called Nectin-4 is safe and how well the cancer responds to the study drug. LY4052031 has not been approved by the US Food and Drug Administration (FDA). This is a first in human study and all of the risks are not fully…
Condition: Stroke
Investigator: Joel Stein, MD
Status: Currently Recruiting
My Hand Project for Stroke Patients: We are testing a robotic device to help people who had a stroke use their weak hand more easily. This research study would involve you wearing a hand robot that helps open and close your fingers in order to use your hand to pick up common everyday objects. During the study, you may be asked to try out different…
Condition: Cancer / Bladder Cancer
Investigator: Andrew Lenis, MD
Status: Closed
This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual therapy? The usual approach for patients who are not in a study is treatment with Transurethral surgery of bladder tumor (…
Condition: Stroke
Investigator: Lenin Grajo, PhD
Status: Closed
This program aims to help improve adult caregivers of stroke survivors ability to care for their stroke survivors with their daily needs. Each session will cover different topics which are important for caregivers to understand in order to best engage in their new role. Topics will include, but are not limited to: bathing, toileting, dressing, transfers,…
Condition: Stroke
Investigator: Dawn Nilsen, EdD, OTR/L, FAOTA
Status: Closed
The purpose of this research is to learn about types of practice that may benefit stroke survivors when learning to use their weaker arm to perform a task. Potential participants will be asked to come to Columbia University Irving Medical Center (CUIMC) for a screening session. Eligible participants will be randomized into two groups with different practice…
Condition: Cancer / Bladder Cancer
Investigator: Christopher Anderson, MD
Status: Closed
This study is for patients who have bladder cancer that has not invaded muscle tissue and who have been treated with one or more surgical resections and Bacillus Calmette-Guerin or BCG, which was directly given into the bladder before. The main purpose of this trial is to show that durvalumab is safe when given alone, in combination with BCG treatments, and…
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3b of AL amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to compare the effects.
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3a of amyloid light chain (AL) amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
We are doing this research to find out the safety, toxicity, and efficacy of intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of non-muscle-invasive urothelial carcinoma of the bladder that has recurred despite BCG use. The purpose of finding the maximum tolerable dose is important for future use of the drug, so as to provide the…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This is a Phase 1 study (the first time this treatment is being tested in humans) of an anti-cancer study drug called as PF-07225570. This study drug works on stimulating certain cells in the immune system. The study will test different doses that increase (dose escalation) and at the appropriate time, additional patients will be enrolled to evaluate this…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of an antibody drug (STI-6129) in patients with AL amyloidosis that has returned or has not responded to treatment (relapsed/refractory). The study drug (STI-6129) will be given in 3 injections through a needle, into a vein as an intravenous (IV), with 21 days between each injection.
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This research study will investigate an experimental, unapproved drug that will be given two different ways; as an injection in the bladder wall after bladder tumor resection surgery (or TURBT) and then as an intravesical instillation (fluid inserted in the bladder by catheter) right after the injection. The purpose of this study is to find the dose which…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The study is part of a research program to assess the efficacy of the drug nab-rapamycin, a biologic mTOR inhibitor. The purpose of the study is to assess the response rate, as well as, the safety of administering nab-rapamycin in combination with gemcitabine directly into the bladder in an effort to treat bladder cancer. The study seeks to determine if…
Condition: Cancer / Bladder Cancer
Investigator: Christopher Anderson, MD
Status: Closed
This research is being done to study the effects, safety, and tolerability of the study drugs Nivolumab and Urelumab when given to people with advanced bladder cancer that has spread into the muscle tissue, also called Muscle-Invasive Urothelial Carcinoma of the Bladder (MIBC). Specifically, this research study will have participants either take Nivolumab…
Condition: Stroke
Investigator: Joel Stein, MD
Status: Closed
We are looking for adults who have had a stroke to participate in testing of a new robotic device for the hand. If you had a stroke over six months ago and now have difficulty using your hand, you may qualify to participate in this study. Time commitment: ~4 weeks, 3x/week, Compensation: $50 per testing visit, $25 per training session.
Condition: Stroke
Investigator: Joel Stein, MD
Status: Closed
Stroke often results in limitation of arm movements, from which many people do not fully recover. We believe that early and intensive therapy is important to enhance recovery of arm movements after stroke. We are doing this research study to see how much arm movements improve with intensive therapy in patients have had a stroke in the past 5 weeks. We will…
Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) also known as Familial Amyloid Polyneuropathy (FAP), and determine if it can help people with mild or moderate polyneuropathy. To be in this study you must have FAP and be…
Condition: Cancer / Bladder Cancer
Investigator: Emerson Lim, MD
Status: Closed
The purpose of this study is to test how well the drug works, safety, and side effects of the experimental drug called BMS-986205. BMS-986205 will be added to another cancer medicine called nivolumab plus chemotherapy for participants who have bladder cancer that has grown into the muscle wall of the bladder. These drugs will be compared to just…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to evaluate whether study drug NEOD001 will improve survival in subjects with AL amyloidosis and/or increase the interval of time that they can go without requiring hospitalization for problems with their hearts. This study will also evaluate whether NEOD001 improves the function of subjects' organs that have been affected…
Condition: Cancer / Bladder Cancer
Investigator: Mark Stein, MD
Status: Closed
This clinical trial is for patients who have cancer of the urinary system (urothelial cancer, including cancer of the bladder, renal pelvis, ureter or urethra) that has spread to nearby tissues or to other areas of the body who have already been treated with a kind of anticancer drug called an immune checkpoint inhibitor (CPI). This clinical trial uses an…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to find out if MLN9708 plus dexamethasone improves against systemic light chain amyloidosis better than the physicians choice chemotherapy treatment. Physicians choice chemotherapy treatment is a treatment regimen that is commonly used to treat amyloidosis patients. The study will also determine if MLN9708 plus dexamethasone can…
Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
HELIOS-A is a global Phase 3 randomized, open-label study designed to evaluate the safety and efficacy of ALN-TTRSC02 in adult patients with hATTR amyloidosis experiencing neurologic symptoms brought on by the disease. The study will also evaluate any changes in quality of life experienced by study participants. ALN-TTRSC02 utilizes the mechanism of RNA…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The purpose of this study is to look at a new treatment for non-muscle-invasive bladder cancer. This new form of paclitaxel, a drug currently used by injection into a vein to treat various types of cancer, is designed to be instilled (injected) into the urinary bladder with a catheter (tube) placed into your bladder through your urethra (the opening where…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects that have been previously treated for systemic light chain (AL)amyloidosis (a disease in which abnormal protein deposits can damage organs and tissues in your body) and nowrequire further treatment. The main purpose of this study is to evaluate the safety and determine the maximum tolerated dose of aninvestigational new…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to test for any good and bad effects of the study drug called isatuximab. Isatuximab may or may not improve your AL amyloidosis, but it could also cause side effects. Isatuximab is not approved by the Food and Drug Administration (FDA). Isatuximab has been shown to have good effects in some patients with recurring multiple…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This study is being conducted to evaluate the performance of the AssureMDx test for the detection of bladder cancer in patients presenting with hematuria.
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The study is being done to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment. Bendamustine is currently approved by the Food and Drug Administration (FDA) for treatment of chronic lymphocytic leukemia (CLL) and is under clinical development in the United States for the…
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to see if daratumumab when given with three other drugs cyclophosphamide, bortezomib (VELCADE) and dexamethasone is useful for treating patients with Amyloid light chain Amyloidosis (also known as AL Amyloidosis). The study will look at what happens (both good and bad) when daratumumab is given with these three drugs compared to…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The purposes of this clinical study are: To evaluate the safety and tolerability of up to 2 drug release periods of GemRIS for up to 7 days per drug release period To evaluate the pharmacokinetics (the study of the bodily absorption, distribution, metabolism, and excretion of the drug) of gemcitabine and a gemcitabine-related metabolite (product after…
Condition: Stroke
Investigator: Robert Sommer, MD
Status: Closed
The Amulet IDE trial is a prospective, randomized, multi-center active control worldwide trial, designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device (treatment) or a Boston Scientific WATCHMAN LAA closure device (Control).…